PBM
ABEO icon

Propel Bio Management’s Abeona Therapeutics ABEO Stock Holding History

Propel Bio Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.01M Buy
1,329,899
+499,119
+60% +$2.5M 3.79% 6
2025
Q4 		$4.38M Sell
830,780
-143,242
-15% -$721K 3.74% 10
2025
Q3 		$5.14M Hold
974,022
– – 5.15% 7
2025
Q2 		$5.53M Buy
974,022
+350,000
+56% +$1.99M 6.71% 5
2025
Q1 		$2.97M Hold
624,022
– – 3.45% 8
2024
Q4 		$3.48M Hold
624,022
– – 3.45% 10
2024
Q3 		$3.94M Sell
624,022
-624,022
-50% -$3.26M 2.29% 11
2024
Q2 		$5.29M Buy
+1,248,044
New +$6.37M 3.43% 10

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Propel Bio Management's ABEO Position: Q1 2026 in Review

Propel Bio Management increased its Abeona Therapeutics (ABEO) stake by 60% in Q1 2026, buying an estimated $2.5M and bringing the position to 1,329,899 shares worth $6.01M. The position accounts for 3.79% of the portfolio, ranked #6.

Propel Bio Management first reported a position in ABEO in Q2 2024 and has held it in 8 quarters since. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Propel Bio Management held 1,329,899 shares of Abeona Therapeutics worth $6.01M as of Q1 2026.
  • Propel Bio Management bought 499,119 Abeona Therapeutics shares in Q1 2026, an estimated $2.5M.
  • Abeona Therapeutics made up 3.79% of Propel Bio Management's portfolio in Q1 2026, its #6 holding.
  • Propel Bio Management first reported a position in Abeona Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.